Title

Somatostatin Receptor-Targeted Radionuclide Therapy of Neuroendocrine Tumours

Authoring Organization

Publication Month/Year

October 4, 2024

Last Updated Month/Year

October 18, 2024

Document Type

Guideline

Country of Publication

US

Document Objectives

This guidance document is aimed at assisting and guiding nuclear medicine specialists in:
1. Assessing patients with well-differentiated neuroendocrine tumours (NETs) for their eligibility to undergo treatment with peptide receptor radionuclide therapy (PRRT).
2. Providing guidance on performing PRRT and implementing this treatment in a safe and effective manner.
3. Understanding and evaluating the outcome of PRRT, namely treatment results and possible side effects, including both renal and haematological toxicities.

Inclusion Criteria

Male, Female, Adult, Older adult

Health Care Settings

Outpatient, Radiology services

Intended Users

Nurse, nurse practitioner, physician, physician assistant, radiology technologist

Scope

Treatment, Management

Diseases/Conditions (MeSH)

D018358 - Neuroendocrine Tumors

Keywords

Somatostatin receptor, neuroendocrine tumors, Radionuclide Therapy, Somatostatin, PRRT